AVITA Medical Inc RCEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RCEL is a good fit for your portfolio.
News
-
AVITA Medical to Announce First Quarter 2024 Financial Results
-
AVITA Medical Updates Expected First Quarter 2024 Revenue
-
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
-
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
-
AVITA Medical to Host Investor Webinar Briefing
-
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
-
AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
-
AVITA Medical Gets FDA Approval on Vitiligo Treatment
Trading Information
- Previous Close Price
- $9.70
- Day Range
- $9.34–9.88
- 52-Week Range
- $9.16–21.70
- Bid/Ask
- $9.51 / $10.34
- Market Cap
- $241.13 Mil
- Volume/Avg
- 227,564 / 222,907
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.90
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 207
- Website
- https://www.avitamedical.com
Competitors
Valuation
|
Metric
|
RCEL
|
FPH
|
NAN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 57.28 | 54.78 |
Price/Book Value | 4.96 | 8.74 | 4.88 |
Price/Sales | 4.90 | 8.99 | 5.24 |
Price/Cash Flow | — | 39.12 | 36.00 |
Price/Earnings
RCEL
FPH
NAN
Financial Strength
|
Metric
|
RCEL
|
FPH
|
NAN
|
|---|---|---|---|
Quick Ratio | 7.35 | 1.06 | 5.26 |
Current Ratio | 7.88 | 2.54 | 6.56 |
Interest Coverage | −30.10 | 25.77 | 12.46 |
Quick Ratio
RCEL
FPH
NAN
Profitability
|
Metric
|
RCEL
|
FPH
|
NAN
|
|---|---|---|---|
Return on Assets (Normalized) | −37.61% | 12.48% | 9.04% |
Return on Equity (Normalized) | −50.88% | 16.75% | 11.94% |
Return on Invested Capital (Normalized) | −44.09% | 15.46% | 9.96% |
Return on Assets
RCEL
FPH
NAN
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Jznzsfs | Pgpzbn | $183.8 Bil | |
SYK
| Stryker Corp | Lthzmpfdhy | Rdpt | $127.8 Bil | |
MDT
| Medtronic PLC | Pxlrdfhnn | Swttc | $105.0 Bil | |
BSX
| Boston Scientific Corp | Gzwjjsyc | Tqtryd | $99.9 Bil | |
EW
| Edwards Lifesciences Corp | Pwtyzkdmqg | Ytdyydk | $52.5 Bil | |
DXCM
| DexCom Inc | Csxybqqgg | Rwmd | $51.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Kfpyknqsn | Mnvg | $24.9 Bil | |
ALGN
| Align Technology Inc | Xbthgphwj | Rwdjzv | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Xvkbnghqc | Qrywfy | $18.5 Bil | |
PODD
| Insulet Corp | Thgybynyy | Wdnlvh | $11.6 Bil |